Recurrent high-grade glioma: a diagnostic and therapeutic challenge

References

• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Prados MD, Gutin PH, Phillips TL et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int. J. Radiat. Oncol. Biol. Phys.23(1), 3–8 (1992).
   PubMed Web of Science ®Google Scholar
• Prados MD, Seiferheld W, Sandler HM et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int. J. Radiat. Oncol. Biol. Phys.58(4), 1147–1152 (2004).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer Phase III trial. J. Clin. Oncol.24(18), 2715–2722 (2006).
   PubMed Web of Science ®Google Scholar
• Lamborn KR, Yung WK, Chang SM et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol.10(2), 162–170 (2008).
   PubMed Web of Science ®Google Scholar
• Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol.17(8), 2572–2578 (1999).
   PubMed Web of Science ®Google Scholar
• Yung WK, Albright RE, Olson J et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer83(5), 588–593 (2000).
   PubMed Web of Science ®Google Scholar
• Levin VA, Ictech S, Hess KR. Impact of Phase II trials with progression-free survival as end-points on survival-based Phase III studies in patients with anaplastic gliomas. BMC Cancer7, 106 (2007).
   PubMedGoogle Scholar
• Walbert T, Gilbert MR, Groves MD et al. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. J. Neurooncol.102(2), 273–280 (2011).
   PubMedGoogle Scholar
• Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for Phase II studies of supratentorial malignant glioma. J. Clin. Oncol.8(7), 1277–1280 (1990).
   PubMed Web of Science ®Google Scholar
• Kumar AJ, Leeds NE, Fuller GN et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology217(2), 377–384 (2000).
   PubMed Web of Science ®Google Scholar
• Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology59(6), 947–949 (2002).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol.26(13), 2192–2197 (2008).
   PubMed Web of Science ®Google Scholar
• Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer113(2), 405–410 (2008).
   PubMed Web of Science ®Google Scholar
• Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys.65(2), 499–508 (2006).
   PubMed Web of Science ®Google Scholar
• Shrieve DC, Alexander E 3rd, Wen PY et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery36(2), 275–282; discussion 282–274 (1995).
   PubMed Web of Science ®Google Scholar
• Chen W. Clinical applications of PET in brain tumors. J. Nucl. Med.48(9), 1468–1481 (2007).
   PubMed Web of Science ®Google Scholar
• Soares DP, Law M. Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin. Radiol.64(1), 12–21 (2009).
   PubMed Web of Science ®Google Scholar
• Young GS. Advanced MRI of adult brain tumors. Neurol. Clin.25(4), 947–973, viii (2007).
   PubMedGoogle Scholar
• Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11(1), 83–95 (2007).
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol.25(30), 4722–4729 (2007).
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol.28(11), 1963–1972 (2010).
   PubMed Web of Science ®Google Scholar
• Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg.95(2), 190–198 (2001).
   PubMed Web of Science ®Google Scholar
• Romanelli P, Conti A, Pontoriero A et al. Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma multiforme. Neurosurg. Focus27(6), E8 (2009).
   PubMedGoogle Scholar
• Mahajan A, McCutcheon IE, Suki D et al. Case–control study of stereotactic radiosurgery for recurrent glioblastoma multiforme. J. Neurosurg.103(2), 210–217 (2005).
   PubMed Web of Science ®Google Scholar
• Fogh SE, Andrews DW, Glass J et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J. Clin. Oncol.28(18), 3048–3053 (2010).
   PubMed Web of Science ®Google Scholar
• Gutin PH, Iwamoto FM, Beal K et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys.75(1), 156–163 (2009).
   PubMed Web of Science ®Google Scholar
• Yung WK, Prados MD, Yaya-Tur R et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol.17(9), 2762–2771 (1999).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Paz MF, Yaya-Tur R, Rojas-Marcos I et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin. Cancer Res.10(15), 4933–4938 (2004).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Dubbink HJ, Sanson M et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J. Clin. Oncol.27(35), 5881–5886 (2009).
   PubMed Web of Science ®Google Scholar
• Weller M, Stupp R, Reifenberger G et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat. Rev. Neurol.6(1), 39–51 (2010).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Franceschi E, Tosoni A et al. O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro Oncol.12(3), 283–288 (2010).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Cavallo G et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from Gruppo Italiano Cooperativo di Neuro-oncologia (GICNO). Br. J. Cancer95(9), 1155–1160 (2006).
   PubMed Web of Science ®Google Scholar
• Perry JR, Belanger K, Mason WP et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J. Clin. Oncol.28(12), 2051–2057 (2010).
   PubMed Web of Science ®Google Scholar
• Wick A, Felsberg J, Steinbach JP et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J. Clin. Oncol.25(22), 3357–3361 (2007).
   PubMed Web of Science ®Google Scholar
• Wick A, Pascher C, Wick W et al. Rechallenge with temozolomide in patients with recurrent gliomas. J. Neurol.256(5), 734–741 (2009).
   PubMed Web of Science ®Google Scholar
• Brada M, Stenning S, Gabe R et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J. Clin. Oncol.28(30), 4601–4608 (2010).
   PubMed Web of Science ®Google Scholar
• Kong DS, Lee JI, Kim JH et al. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol.12(3), 289–296 (2010).
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet345(8956), 1008–1012 (1995).
   PubMed Web of Science ®Google Scholar
• Quinn JA, Jiang SX, Carter J et al. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin. Cancer Res.15(3), 1064–1068 (2009).
   PubMed Web of Science ®Google Scholar
• Kunwar S, Chang S, Westphal M et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol.12(8), 871–881 (2010).
   PubMedGoogle Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol.22(1), 133–142 (2004).
   PubMed Web of Science ®Google Scholar
• Franceschi E, Cavallo G, Lonardi S et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre Phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br. J. Cancer96(7), 1047–1051 (2007).
   PubMed Web of Science ®Google Scholar
• Raymond E, Brandes AA, Dittrich C et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J. Clin. Oncol.26(28), 4659–4665 (2008).
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Yoshimoto K, Nghiemphu P et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med.5(1), e8 (2008).
   PubMed Web of Science ®Google Scholar
• Galanis E, Jaeckle KA, Maurer MJ et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J. Clin. Oncol.27(12), 2052–2058 (2009).
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Reardon DA. Targeting multiple kinases in glioblastoma multiforme. Expert Opin. Investig. Drugs18(3), 277–292 (2009).
   PubMed Web of Science ®Google Scholar
• Gossage L, Eisen T. Targeting multiple kinase pathways: a change in paradigm. Clin. Cancer Res.16(7), 1973–1978 (2010).
   PubMed Web of Science ®Google Scholar
• Wang MY, Lu KV, Zhu S et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res.66(16), 7864–7869 (2006).
   PubMed Web of Science ®Google Scholar
• Huang PH, Mukasa A, Bonavia R et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl Acad. Sci. USA104(31), 12867–12872 (2007).
   PubMed Web of Science ®Google Scholar
• Lal B, Goodwin CR, Sang Y et al. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Mol. Cancer Ther.8(7), 1751–1760 (2009).
   PubMed Web of Science ®Google Scholar
• Guo A, Villen J, Kornhauser J et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl Acad. Sci. USA105(2), 692–697 (2008).
   PubMed Web of Science ®Google Scholar
• Terstappen GC, Schlupen C, Raggiaschi R, Gaviraghi G. Target deconvolution strategies in drug discovery. Nat. Rev. Drug Discov.6(11), 891–903 (2007).
   PubMed Web of Science ®Google Scholar
• Dong X, Guan J, English JC et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin. Cancer Res.16(5), 1442–1451 (2010).
   PubMed Web of Science ®Google Scholar
• Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M. Drug-target network. Nat. Biotechnol.25(10), 1119–1126 (2007).
   PubMed Web of Science ®Google Scholar
• Huang PH, Xu AM, White FM. Oncogenic EGFR Signaling Networks in Glioma. Sci. Signal.2(87), re6 (2009).
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Desjardins A, Vredenburgh JJ et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol.12(12), 1300–1310 (2010).
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Grimm S, Chamberlain MC et al. A Phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer116(22), 5297–5305 (2010).
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol.27(28), 4733–4740 (2009).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol.28(17), 2817–2823 (2010).
   PubMed Web of Science ®Google Scholar
• Malkin MG, Rosen L, Lopez AM, Mulay M, Cloughesy T, Hannah AL. Phase 2 study of SU101, a PDGF-R signal transduction inhibitor, in recurrent malignant glioma. Presented at: American Society of Clinical Oncology Annual Meeting, CA, USA, 16–19 May 1998.
   Google Scholar
• Mikkelsen T, Brodie C, Finniss S et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int. J. Cancer124(11), 2719–2727 (2009).
   PubMed Web of Science ®Google Scholar
• Nabors LB, Mikkelsen T, Rosenfeld SS et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol.25(13), 1651–1657 (2007).
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Neyns B et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol.28(16), 2712–2718 (2010).
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N. Engl. J. Med.359(5), 492–507 (2008).
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Mischel PS. New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clin. Cancer Res.17(1), 6–11 (2011).
   PubMedGoogle Scholar
• Desjardins A, Reardon DA, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin. Cancer Res.14(21), 7068–7073 (2008).
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol.27(5), 740–745 (2009).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Vredenburgh JJ et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a Phase II study. Br. J. Cancer101(12), 1986–1994 (2009).
   PubMed Web of Science ®Google Scholar